Clinical Trials

MainTitle

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (DRIVE-FORWARD)

This study is ongoing, but not recruiting participants.
Sponsor
Merck Sharp & Dohme Corp.


Information provided by (Responsible Party)
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier
NCT02275780

First received: October 23, 2014
Last updated: April 14, 2020
Last Verified: April 2020
History of Changes
Purpose

Purpose

To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1. Eligible participants who are deriving benefit will continue in Study Extension 2 to receive the doravirine-containing regimen open label until doravirine becomes locally available or for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.

Condition Intervention Phase
HIV-1

Drug : Doravirine
Drug : Darunavir
Drug : Ritonavir
Drug : TRUVADA™ or EPZICOM™/KIVEXA™
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures

  • Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48 [ Time Frame: Week 48 ]
    The percentage of participants in each arm achieving HIV-1 RNA levels <50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Secondary Outcome Measures:
  • Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96 [ Time Frame: Week 96 ]
    The percentage of participants in each arm achieving HIV-1 RNA levels <50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
  • Change From Baseline in Mean CD4+ T-cell Count at Week 48 [ Time Frame: Baseline and Week 48 ]
    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
  • Change From Baseline in Mean CD4+ T-cell Count at Week 96 [ Time Frame: Baseline and Week 96 ]
    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
  • Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting Total Cholesterol at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting Triglyceride at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Percentage of Participants With Any Adverse Event [ Time Frame: Up to 98 weeks ]
    An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.
  • Percentage of Participants With Any Serious Adverse Event [ Time Frame: Up to 98 weeks ]
    A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.
  • Percentage of Participants With Any Drug-related Adverse Event [ Time Frame: Up to 98 weeks ]
    The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.
  • Percentage of Participants With Any Drug-related Serious Adverse Event [ Time Frame: Up to 98 weeks ]
    The percentage of participants with any drug-related SAE was assessed.
  • Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event [ Time Frame: Up to 96 weeks ]
    The percentage of participants who discontinued study treatment due to an AE was assessed.
  • Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48 [ Time Frame: Week 48 ]
    The percentage of participants in each arm achieving HIV-1 RNA levels <40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
  • Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96 [ Time Frame: Week 96 ]
    The percentage of participants in each arm achieving HIV-1 RNA levels <40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

Enrollment: 769
Study Start Date: December 1, 2014
Estimated Study Completion Date: June 23, 2021
Estimated Primary Completion Date: September 29, 2016 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Doravirine 100 mg
Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
Drug: Doravirine

Doravirine 100 mg tablet administered p.o., q.d.

Drug: TRUVADA™ or EPZICOM™/KIVEXA™

The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, p.o., q.d., or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o., q.d.

Active Comparator: Darunavir 800 mg and Ritonavir 100 mg
Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
Drug: Doravirine

Doravirine 100 mg tablet administered p.o., q.d.

Drug: Darunavir

Darunavir 800 mg tablet administered p.o., q.d.

Drug: Ritonavir

Ritonavir 100 mg tablet administered p.o., q.d.

Drug: TRUVADA™ or EPZICOM™/KIVEXA™

The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, p.o., q.d., or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o., q.d.

Detailed Description:

Participants in Australia, Russia, and South Africa who are deriving benefit from MK-1439A are also eligible to continue receiving study drug during Study Extension 3, which will last for 2 years or until drug is available locally, whichever comes first.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
  • Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretroviral agents.
  • Is considered clinically stable with no signs or symptoms of active infection for at least 2 weeks prior to the start of treatment.
  • Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate a partner because they are not of reproductive potential, or agree to practice abstinence or use acceptable contraception for up to 14 days after the last dose of study drug.
  • Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96 visit, 2) derived benefit from participation through Week 96 in the opinion of the investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of treatment with the Study Extension regimen.
  • Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192 visit, 2) derived benefit from participation through Week 192 in the opinion of the investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with the Study Extension regimen.


Exclusion Criteria:
  • Uses or has had a recent history of using recreational or illicit drugs.
  • Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1.
  • Has documented or known resistance to study drugs including doravirine, darunavir, ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.
  • Has participated in a study with an investigational compound/device within the prior month, or anticipates doing so during this study.
  • Has used systemic immunosuppressive therapy or immune modulators within the prior 30 days, or anticipates doing so during this study.
  • Has significant hypersensitivity or other contraindication to any of the components of the study drugs.
  • Has a current (active) diagnosis of acute hepatitis due to any cause.
  • Is pregnant, breastfeeding or expecting to conceive at any time during the study.
  • Female who expects to donate eggs, or male who expects to donate sperm at any time
during the study.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02275780

Sponsors and Collaborators

Merck Sharp & Dohme Corp.

Investigators

Study Director: Medical Director Merck Sharp & Dohme Corp.
More Information

More Information


Responsible Party: Merck Sharp & Dohme Corp.  
ClinicalTrials.gov Identifier: NCT02275780   History of Changes  
Other Study ID Numbers: 1439-018  
  2014-001127-69  
  MK-1439-018  
Study First Received: October 23, 2014  
Last Updated: April 14, 2020  
Individual Participant Data    
Plan to Share IPD: Yes  

Additional relevant MeSH terms:
Ritonavir
Darunavir
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

ClinicalTrials.gov processed this data on June 02, 2020
This information is provided by ClinicalTrials.gov.